Topic: How To Invest

I would like to have your opinion on this stock: Novo Nordisk A/S on New York.

Article Excerpt

Novo Nordisk A/S (ADR), $103.84, symbol NVO on New York (Shares outstanding: 465.7 million; Market cap: $48.4 billion; www.novonordisk.com), is a major maker of insulin and diabetes-care products, as well as treatments for coagulation disorders, such as hemophilia. The company also makes hormone replacement therapy products. Denmark-based Novo Nordisk supplies 51% of world insulin demand. The company gets 37% of its sales from North America, followed by the European Union (34%), Japan and the Asia-Pacific region (11%), and other parts of the world (18%). Novo Nordisk spends a high 15.4% of its sales on research and development. The company’s outlook is positive. Its sales continue to rise, and the North American market, in particular, offers a chance to increase its already high market share in diabetes-care products. As well, the company’s high research spending is helping it develop a number of promising products. It is mainly focused on its Degludec and DegludecPlus insulins, which are designed to last over 24 hours…